ATE440828T1 - 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen - Google Patents
4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungenInfo
- Publication number
- ATE440828T1 ATE440828T1 AT04811612T AT04811612T ATE440828T1 AT E440828 T1 ATE440828 T1 AT E440828T1 AT 04811612 T AT04811612 T AT 04811612T AT 04811612 T AT04811612 T AT 04811612T AT E440828 T1 ATE440828 T1 AT E440828T1
- Authority
- AT
- Austria
- Prior art keywords
- furan
- dihydro
- oxo
- derivatives
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 239000003086 colorant Substances 0.000 abstract 1
- 239000003973 paint Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52426903P | 2003-11-21 | 2003-11-21 | |
| PCT/US2004/038920 WO2005051937A2 (en) | 2003-11-21 | 2004-11-18 | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE440828T1 true ATE440828T1 (de) | 2009-09-15 |
Family
ID=34632884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04811612T ATE440828T1 (de) | 2003-11-21 | 2004-11-18 | 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20070093545A1 (enExample) |
| EP (1) | EP1701947B1 (enExample) |
| JP (1) | JP2007512346A (enExample) |
| CN (1) | CN1882557A (enExample) |
| AT (1) | ATE440828T1 (enExample) |
| AU (1) | AU2004293415A1 (enExample) |
| CA (1) | CA2545823A1 (enExample) |
| DE (1) | DE602004022864D1 (enExample) |
| ES (1) | ES2331521T3 (enExample) |
| WO (1) | WO2005051937A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094572B2 (en) | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
| JP5254620B2 (ja) | 2004-12-03 | 2013-08-07 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｃｂ１アンタゴニストとしての置換ピペラジン |
| KR100826108B1 (ko) * | 2006-08-04 | 2008-04-29 | 한국화학연구원 | 퓨란-2-카복실산 유도체 및 그의 제조 방법 |
| US20110082202A1 (en) * | 2009-10-05 | 2011-04-07 | Milne Jill C | Fatty acid acifran derivatives and their uses |
| WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| WO2018006258A1 (en) * | 2016-07-05 | 2018-01-11 | Shenzhen Xpectvision Technology Co., Ltd. | Bonding materials of dissimilar coefficients of thermal expansion |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4169202A (en) * | 1978-06-05 | 1979-09-25 | American Home Products Corporation | Process for preparing 4,5-dihydro-4-oxofuran-2-carboxylic acid derivatives |
| US4244958A (en) * | 1979-05-10 | 1981-01-13 | American Home Products Corporation | Hypolipidemic derivatives of 4,5-dihydro-4-oxofuran-2-carboxylic acid |
| US6902902B2 (en) * | 2001-11-27 | 2005-06-07 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders |
| WO2004033431A2 (en) | 2002-10-04 | 2004-04-22 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
| AU2003300014A1 (en) | 2002-10-10 | 2004-05-04 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
| WO2004041274A1 (en) | 2002-11-05 | 2004-05-21 | Arena Pharmaceuticals, Inc. | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof |
| AU2004260636A1 (en) | 2003-06-13 | 2005-02-10 | Arena Pharmaceuticals, Inc. | 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases |
| TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
| CA2584225A1 (en) | 2004-11-05 | 2006-05-18 | Arena Pharmaceuticals, Inc. | Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| JP2008538277A (ja) | 2005-02-18 | 2008-10-23 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 脂質関連障害の治療用の組成物および方法 |
| WO2006127595A1 (en) | 2005-05-23 | 2006-11-30 | Arena Pharmaceuticals, Inc. | 5-aminopyrazole carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof |
| EP1924709A1 (en) | 2005-08-10 | 2008-05-28 | Arena Pharmaceuticals, Inc. | Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist |
-
2004
- 2004-11-18 AU AU2004293415A patent/AU2004293415A1/en not_active Abandoned
- 2004-11-18 AT AT04811612T patent/ATE440828T1/de not_active IP Right Cessation
- 2004-11-18 DE DE602004022864T patent/DE602004022864D1/de not_active Expired - Lifetime
- 2004-11-18 JP JP2006541430A patent/JP2007512346A/ja active Pending
- 2004-11-18 CA CA002545823A patent/CA2545823A1/en not_active Abandoned
- 2004-11-18 EP EP04811612A patent/EP1701947B1/en not_active Expired - Lifetime
- 2004-11-18 CN CNA2004800340741A patent/CN1882557A/zh active Pending
- 2004-11-18 ES ES04811612T patent/ES2331521T3/es not_active Expired - Lifetime
- 2004-11-18 US US10/578,732 patent/US20070093545A1/en not_active Abandoned
- 2004-11-18 WO PCT/US2004/038920 patent/WO2005051937A2/en not_active Ceased
-
2006
- 2006-11-21 US US11/602,551 patent/US7803837B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7803837B2 (en) | 2010-09-28 |
| CN1882557A (zh) | 2006-12-20 |
| AU2004293415A1 (en) | 2005-06-09 |
| EP1701947B1 (en) | 2009-08-26 |
| DE602004022864D1 (de) | 2009-10-08 |
| ES2331521T3 (es) | 2010-01-07 |
| WO2005051937A3 (en) | 2005-09-15 |
| CA2545823A1 (en) | 2005-06-09 |
| EP1701947A2 (en) | 2006-09-20 |
| US20070161701A1 (en) | 2007-07-12 |
| US20070093545A1 (en) | 2007-04-26 |
| WO2005051937A2 (en) | 2005-06-09 |
| JP2007512346A (ja) | 2007-05-17 |
| WO2005051937A8 (en) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005015397D1 (de) | Leuchtstoff, Verfahren zu seiner Herstellung und diesen Leuchtstoff verwendende Lichtquelle | |
| DE60143850D1 (de) | Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen | |
| ATE309182T1 (de) | Gleichmässig gefärbte gerüstkeramik sowie färbelösung | |
| DE602004030239D1 (de) | Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon | |
| DE60320527D1 (de) | Verfahren zur herstellung von grünteepolyphenol | |
| ATE495739T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| DE112004000210D2 (de) | Beschichteter Leuchtstoff, lichtemittierende Vorrichtung mit derartigem Leuchtstoff und Verfahren zu seiner Herstellung | |
| ATE529793T1 (de) | Vorrichtung und verfahren zur kontinuierlichen herstellung von farben mit automatischer anpassung der farbe | |
| DE60210695D1 (de) | Farbstoff zum Färben von Kontaktlinsen und Verfahren zur Herstellung gefärbter Kontaktlinsen | |
| DE60316152D1 (de) | Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen | |
| DE50209217D1 (de) | Verfahren zur Herstellung von Polyisocyanaten der Diphenylmethanreihe mit vermindertem Farbwert | |
| ATE440828T1 (de) | 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen | |
| DE502004002125D1 (de) | Mischkristalle mit derivaten von c.i. pigment red 170 | |
| EP1670894A4 (en) | COMPOSITIONS COMPRISING VARIOUS TYPES OF TRANSFER FACTOR, METHODS FOR PREPARING COMPOSITIONS, AND METHODS OF TREATMENT USING THE COMPOSITIONS | |
| DE60220554D1 (de) | Mikrowelleninduzierter prozess zur herstellung von substituierten 4-vinylphenolen | |
| DE502005000428D1 (de) | Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen | |
| AU2003256100A1 (en) | Coloring method of natural leather, and colored natural leather using the same | |
| ATE549023T1 (de) | Formulierungen mit jorumycin-, renieramycin-, safracin- oder saframycin-verwandten verbindungen und einen disaccharide zur behandlung von proliferativen erkrankungen | |
| DE502006002680D1 (de) | Verfahren zur herstellung von feinteiligem c.i. pigment red 254 | |
| DE60313157D1 (de) | Ein verfahren zur herstellung von clopidogrel | |
| ATE446299T1 (de) | Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin | |
| ATE538209T1 (de) | L-threonin herstellendes bakterium und verfahren zur herstellung von l-threonin | |
| DE602005016282D1 (de) | Verfahren zur herstellung von camptothecin-derivaten | |
| DE50300920D1 (de) | Ferrocenylliganden und ein verfahren zur herstellung solcher liganden | |
| DE502004002371D1 (de) | Verfahren zur herstellung von transparenten pigmentzubereitungen auf basis von perylen-3,4,9,10-tetracarbons urediimid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |